These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 33812679)

  • 41. SGLT2 inhibitors in the treatment of type 2 diabetes.
    Hasan FM; Alsahli M; Gerich JE
    Diabetes Res Clin Pract; 2014 Jun; 104(3):297-322. PubMed ID: 24735709
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Sodium-glucose cotransporter 2 inhibitors represent a paradigm shift in the prevention of heart failure in type 2 diabetes patients.
    Kashiwagi A; Araki S; Maegawa H
    J Diabetes Investig; 2021 Jan; 12(1):6-20. PubMed ID: 32563214
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Heart failure hospitalization risk associated with use of two classes of oral antidiabetic medications: an observational, real-world analysis.
    Gautam S; Agiro A; Barron J; Power T; Weisman H; White J
    Cardiovasc Diabetol; 2017 Jul; 16(1):93. PubMed ID: 28756774
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Renal and Cardiovascular Effects of SGLT2 Inhibition in Combination With Loop Diuretics in Patients With Type 2 Diabetes and Chronic Heart Failure: The RECEDE-CHF Trial.
    Mordi NA; Mordi IR; Singh JS; McCrimmon RJ; Struthers AD; Lang CC
    Circulation; 2020 Nov; 142(18):1713-1724. PubMed ID: 32865004
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The Sweet Spot: Heart Failure Prevention with SGLT2 Inhibitors.
    Vardeny O
    Am J Med; 2020 Feb; 133(2):182-185. PubMed ID: 31494110
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Softening the Stiff Heart: SGLT2 Inhibition and Diastolic Function.
    Connelly K; Cai S
    JACC Cardiovasc Imaging; 2021 Feb; 14(2):408-410. PubMed ID: 33129739
    [No Abstract]   [Full Text] [Related]  

  • 47. Combined SGLT1 and SGLT2 Inhibitors and Their Role in Diabetes Care.
    Danne T; Biester T; Kordonouri O
    Diabetes Technol Ther; 2018 Jun; 20(S2):S269-S277. PubMed ID: 29916741
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Role of SGLT2 Inhibitors in Patients with Diabetes Mellitus and Heart Failure.
    Verbrugge FH
    Curr Heart Fail Rep; 2017 Aug; 14(4):275-283. PubMed ID: 28647919
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [SGLT2 Inhibitors: Rationale and Perspectives of Use in Heart Failure].
    Kobalava ZD; Lazarev PV; Villevalde SV
    Kardiologiia; 2018 Feb; (2):42-54. PubMed ID: 29466200
    [No Abstract]   [Full Text] [Related]  

  • 50. Development of SGLT1 and SGLT2 inhibitors.
    Rieg T; Vallon V
    Diabetologia; 2018 Oct; 61(10):2079-2086. PubMed ID: 30132033
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cardioprotection: SGLT2 blockers in T2DM.
    Barranco C
    Nat Rev Cardiol; 2018 May; 15(5):255. PubMed ID: 29593287
    [No Abstract]   [Full Text] [Related]  

  • 52. Effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on potassium handling in patients with acute heart failure.
    Beusekamp JC; Tromp J; Boorsma EM; Heerspink HJL; Damman K; Voors AA; van der Meer P
    Eur J Heart Fail; 2021 Jun; 23(6):1049-1052. PubMed ID: 33899306
    [No Abstract]   [Full Text] [Related]  

  • 53. Sodium-glucose co-transporter-2 inhibitors in heart failure with reduced ejection fraction: Current evidence and future perspectives.
    Jensen J; Omar M; Kistorp C; Gustafsson F; Køber L; Møller JE; Schou M
    Basic Clin Pharmacol Toxicol; 2022 Jul; 131(1):5-17. PubMed ID: 35510595
    [TBL] [Abstract][Full Text] [Related]  

  • 54. SGLT2 Inhibition Does Not Affect Myocardial Fatty Acid Oxidation or Uptake, but Reduces Myocardial Glucose Uptake and Blood Flow in Individuals With Type 2 Diabetes: A Randomized Double-Blind, Placebo-Controlled Crossover Trial.
    Lauritsen KM; Nielsen BRR; Tolbod LP; Johannsen M; Hansen J; Hansen TK; Wiggers H; Møller N; Gormsen LC; Søndergaard E
    Diabetes; 2021 Mar; 70(3):800-808. PubMed ID: 33334875
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure: Proposal of a Novel Mechanism of Action.
    Packer M; Anker SD; Butler J; Filippatos G; Zannad F
    JAMA Cardiol; 2017 Sep; 2(9):1025-1029. PubMed ID: 28768320
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Expanding access to newer medicines for people with type 2 diabetes in low-income and middle-income countries: a cost-effectiveness and price target analysis.
    Global Health & Population Project on Access to Care for Cardiometabolic Diseases (HPACC)
    Lancet Diabetes Endocrinol; 2021 Dec; 9(12):825-836. PubMed ID: 34656210
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Genetic Variation in Sodium-glucose Cotransporter 2 and Heart Failure.
    Katzmann JL; Mason AM; März W; Kleber ME; Niessner A; Blüher M; Speer T; Laufs U
    Clin Pharmacol Ther; 2021 Jul; 110(1):149-158. PubMed ID: 33405238
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Potential Therapeutic Effects of Sodium Glucose-linked Cotransporter 2 Inhibitors in Stroke.
    Al Hamed FA; Elewa H
    Clin Ther; 2020 Nov; 42(11):e242-e249. PubMed ID: 33008610
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cardio-renal benefits of sodium-glucose co-transporter 2 inhibitors in heart failure with reduced ejection fraction: mechanisms and clinical evidence.
    Aguilar-Gallardo JS; Correa A; Contreras JP
    Eur Heart J Cardiovasc Pharmacother; 2022 May; 8(3):311-321. PubMed ID: 34264341
    [TBL] [Abstract][Full Text] [Related]  

  • 60. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.
    Zannad F; Ferreira JP; Pocock SJ; Anker SD; Butler J; Filippatos G; Brueckmann M; Ofstad AP; Pfarr E; Jamal W; Packer M
    Lancet; 2020 Sep; 396(10254):819-829. PubMed ID: 32877652
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.